MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

Core Insights - Myriad Genetics, Inc. (MYGN) announced a study published in The Lancet Oncology demonstrating the effectiveness of its Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC), which is expected to enhance the company's Oncology business [1][8] Company Developments - Following the announcement, MYGN shares fell by 2.7% to $6.61, indicating a negative market reaction despite the positive study results [2] - The company has a market capitalization of $615.02 million and has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 210% [3] - The Phase 2 trial of metastasis-directed radiotherapy without systemic therapy (MRWS) for ccRCC was one of the largest conducted in this area, utilizing the Precise MRD Test to evaluate circulating tumor DNA (ctDNA) levels [4][6] Test Performance - The Precise MRD Test is a tumor-informed, whole genome sequencing-based test that monitors numerous tumor-specific variants, allowing for high sensitivity in detecting ctDNA in cancer patients [5] - The study found that ctDNA levels were linked to patient responses to metastasis-directed radiation therapy, with 94% of patients having ctDNA levels below 100 ppm, indicating ultrasensitive testing [6][7] Treatment Implications - Patients who tested negative for ctDNA and continued on MDT had a median treatment duration of 54 months, compared to 27 months for those who tested positive, without compromising overall survival rates of 94% at two years and 87% at three years [7] Industry Outlook - The global MRD testing market is projected to reach $4.50 billion by 2030, growing at a CAGR of 10.1% from 2025 to 2030, driven by increasing cancer incidence, technological advancements, and integration with personalized medicine [9]